IM Biologics Licenses $925mn Antibody Treatment to Navigator Medicines
IM Biologics (CEO Gyongsik Ha) announced on June 17th that it has signed a licensing-out (L/O) agreement with Navigator Medicines, a US-based company, for ‘IMB-101,’ a bispecific antibody-based treatment for… Read More
